Clinical trial · Interventional
Comparison of Contrast Agents in Liver Magnetic Resonance (MR) for the Detection of Hepatic Metastases
Evaluation of Liver Magnetic Resonance (MR) With an Abbreviated Gadobenate Dimeglumine Hepatobiliary Phase Protocol in Comparison to Liver MR With Gadoxetate Disodium for the Detection of Hepatic Metastases
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260926-000001
Why stopped (as posted): Low Accrual
Summary
Brief summary (as posted)
If an abbreviated hepatobiliary phase (HBP) protocol liver MR with gadobenate dimeglumine is shown clinically comparable to standard of care liver MR with gadoxetate disodium for detecting hepatic metastasis from colorectal cancer, its use will save time, cost, and patients' effort.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Liver Metastases | — | UNRESOLVED | — |
| Oligometastatic Disease | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gadobenate dimeglumine | Drug | — | UNRESOLVED |
| Gadoxetate disodium | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Gadoxetate disodium exam first, Gadobenate Dimeglumine exam second
- description
- The subjects will be randomized into two groups. Both groups will undergo two complete protocol liver magnetic resonance imaging (MRI) for known or suspected colorectal cancer (CRC) metastasis, one exam with gadoxetate disodium and the other exam with gadobenate dimeglumine, within an interval of 3-20 days, but in opposite order, determined randomly.
- interventionNames
- Drug: Gadoxetate disodium
- Drug: Gadobenate dimeglumine
- type
- EXPERIMENTAL
- label
- Gadobenate Dimeglumine exam first, Gadoxetate disodium exam second
- description
- The subjects will be randomized into two groups. Both groups will undergo two complete protocol liver MRI for known or suspected CRC metastasis, one exam with gadoxetate disodium and the other exam with gadobenate dimeglumine, within an interval of 3-20 days, but in opposite order, determined randomly.
- interventionNames
- Drug: Gadoxetate disodium
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Colorectal cancer patients * Age 18-80 years * No prior treatment including surgery * Prior imaging with suspected liver metastasis Exclusion Criteria: * Age \< 18 years or \> 80 years * eGFR \< 30 ml/min/1.73 m2 * Previous reaction to gadolinium contrast agents * History of claustrophobia or movement disorders likely to impact image quality * Non-MR safe implants or metallic foreign bodies
References
Publications (0)
Data not yet available